Trials / Completed
CompletedNCT01263899
A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
A Phase 2 Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- S*BIO · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2 study to assess the efficacy of SB1518 in the treatment of patients with advanced lymphoid malignancies including Hodgkin Lymphoma, Mantle Cell Lymphoma and Indolent Lymphoma (follicular lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma and small lymphocytic lymphoma).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SB1518 | SB1518 taken orally daily for 28 consecutive days in a 28 day cycle. |
Timeline
- Start date
- 2010-12-01
- Primary completion
- 2012-02-01
- Completion
- 2012-02-01
- First posted
- 2010-12-21
- Last updated
- 2012-04-20
Locations
5 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT01263899. Inclusion in this directory is not an endorsement.